<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409253</url>
  </required_header>
  <id_info>
    <org_study_id>3738</org_study_id>
    <nct_id>NCT00409253</nct_id>
  </id_info>
  <brief_title>Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine</brief_title>
  <official_title>Treatment of Severe Hypertension During Pre-Eclampsia.A Preliminary Equivalence Study Between URAPIDIL and NICARDIPINE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to confirm that URAPIDIL is as efficient and as safe as NICARDIPINE
      to correct severe hypertension in pre-eclamptic patients.

        -  efficacy endpoint : mean arterial blood pressure corrected to 105-125 mmHg after 120 min
           of study drug administration.

        -  safety endpoints : clinical, biological and ultrasound observation for any side
           effect.All infants will be observed in the neonatology unit (during 48h).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic, diastolic, mean blood pressure and pulse rate :-every 5 min during the titration phase-every 15 min up to the second hour treatment-every hour up to the 6th hour and every 3 hour during the rest of the treatment period.</measure>
    <time_frame>Systolic, diastolic, mean blood pressure and pulse rate :-every 5 min during the titration phase-every 15 min up to the second hour treatment-every hour up to the 6th hour and every 3 hour during the rest of the treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>-maternal and foetal ultrasonography, biology and clinical assessment-type of delivery-post-partum bleeding-neo-natal evaluation by neonatologist during the first 48 hours of life</measure>
    <time_frame>During the first 48hour of life</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Hypertension During Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>Urapidil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicardipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>URAPIDIL (EUPRESSYL*)</intervention_name>
    <description>Urapidil (Eupressyl*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.</description>
    <arm_group_label>Urapidil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NICARDIPINE</intervention_name>
    <description>Nicardipine : IV 6.25 mg bolus until PAD &gt;105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days</description>
    <arm_group_label>Nicardipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  patients 'written informed consent dated and signed by investigator and patient

          -  affiliation to a social security system

          -  single pregnancy

          -  arterial hypertension (PAS ≥140 and/or PAD≥90) in the context of severe pre-eclampsia

        Exclusion criteria:

          -  patient under 18 year old or unable to give informed consent

          -  protocol rejected by patient-impossibility to use non invasive blood pressure
             monitoring

          -  antihypertensive treatments within 24h before inclusion

          -  allergy to or contraindication for one of the study drugs-pre

          -  eclampsia that does not require an antihypertensive treatment

          -  acute eclampsia-requirement for other drugs with potential dangerous interactions with
             study drugs

          -  participation to a therapeutic protocol within 6 months prior to the start of study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Auguste DIEMUNSCH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Auguste DIEMUNSCH, MD</last_name>
    <phone>33.3.88.12.70.78</phone>
    <email>Pierre.Diemunsch@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Saint-Jacques, CHU de Besançon</name>
      <address>
        <city>BESANçON</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam KRAUSZ-GRIGNARD, MD</last_name>
      <phone>33381219014</phone>
      <email>mgrignardkrausz@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Myriam KRAUSZ-GRIGARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludovic VALENTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel SAMAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maternité A. PINARD</name>
      <address>
        <city>Nancy</city>
        <zip>54042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HERVE BOUAZIZ, MD</last_name>
      <phone>33383344490</phone>
      <email>h.bouaziz@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé BOUAZIZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric SAVOYE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves CHALOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nour-Eddine BAKA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie BOILEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence VIAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe JUDLIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier THIEBAUGEORGES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amandine BARBIER-LEREBOURS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sihcus-Cmco</name>
      <address>
        <city>Schiltigheim</city>
        <zip>67303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita VIZITIU, MD</last_name>
      <phone>33388628404</phone>
      <email>rita.vizitiu@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Rita VIZITIU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Germain-Alain AISSI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danielle LE MAHO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Anesthésie et de Réanimation Médicale, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Auguste DIEMUNSCH, MD</last_name>
      <phone>33.3.88.12.70.78</phone>
      <email>Pierre.Diemunsch@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Auguste DIEMUNSCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno LANGER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Israël NISAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves NOUDEM KANA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2006</study_first_submitted>
  <study_first_submitted_qc>December 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2006</study_first_posted>
  <last_update_submitted>February 24, 2009</last_update_submitted>
  <last_update_submitted_qc>February 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christine GEILLER</name_title>
    <organization>Direction de la Recherche Clinique et de l'Innovation - Hôpitaux Universitaires de Strasbourg</organization>
  </responsible_party>
  <keyword>PRE-ECLAMPSIA-URAPIDIL-NICARDIPINE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urapidil</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

